Congratulations to Dr. Tran Le Son of Gene Solutions for receiving the prestigious Conquer Cancer Merit Award at ASCO Breakthrough 2024
💡 His study “Comprehensive validation of a cell-free DNA-based assay for multi-cancer detection: A Vietnamese longitudinal prospective cohort study of 9,024 participants” marks a significant milestone in early cancer detection research.
Conducted on 9,024 healthy participants, this is the first and largest validation study of its kind in Asia, demonstrating that the multi-cancer early detection assay, SPOT-MAS, can be a valuable tool for identifying multiple cancer types at early stages when treatment is most effective.
🌟 Key Findings:
➡️ SPOT-MAS could detect at least 50% of cancer cases with a specificity of 98%, provided the samples contained at least 4.9% ctDNA.
➡️ SPOT-MAS showed a positive predictive value of 58.14%, meaning that out of every 100 people who tested positive, approximately 58 were confirmed to have cancer
➡️ By using the advanced machine learning algorithm, SPOT-MAS can predict where the tumor was located with 84% accuracy
➡️ SPOT-MAS had a very high negative predictive value of 99.92%, an overall sensitivity of 78.13%, and a specificity of 99.80%.
➡️ SPOT-MAS can detect cancers that lack standard-of-care screening options, suggesting that it could complement existing screening programs.
This groundbreaking work emphasizes the importance of accessible and effective screening tools in resource-constrained settings. For a detailed exploration of his findings, read the full abstract here: https://meetings.asco.org/abstracts-presentations/239451
🌟 Access Dr. Son’s interview via this link: https://youtu.be/Jq7WjOUfAkc
📰 Join us at hashtag#ASCOBT2024 in Aug where we would love to connect and collaborate.
#MCED #MCEDawareness #SPOTMAS #KDETEK #SoutheastAsia #mostcommoncancers
